Interpace Biosciences, Inc. (IDXG)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Interpace Biosciences, Inc. (IDXG) with AI Score 51/100 (Hold). Interpace Biosciences, Inc. specializes in molecular diagnostic tests and pathology services, focusing on cancer risk assessment. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Interpace Biosciences, Inc. (IDXG) Healthcare & Pipeline Overview
Interpace Biosciences, Inc. delivers molecular diagnostic solutions for cancer risk assessment, leveraging its PathFinderTG platform. Its key differentiators include PancraGEN and ThyGeNEXT tests, serving physicians and hospitals in the U.S. healthcare sector with a focus on early cancer detection and personalized medicine.
Investment Thesis
Interpace Biosciences, Inc. presents a focused investment opportunity within the molecular diagnostics sector. With a market capitalization of $0.01 billion and a P/E ratio of 1.56, the company demonstrates potential value. A gross margin of 64.6% indicates efficient operations. Key growth catalysts include the expansion of its PancraGEN and ThyGeNEXT testing services. The company's ability to leverage its PathFinderTG platform for new diagnostic applications is a significant value driver. Potential risks include competition from larger diagnostic firms and the need for continuous innovation to maintain market relevance. Investors should monitor the company's ability to expand its customer base and secure favorable reimbursement policies for its tests.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.01B, indicating a small-cap company with potential for growth.
- P/E Ratio of 1.56, suggesting the company may be undervalued compared to its earnings.
- Gross Margin of 64.6%, reflecting efficient cost management in its diagnostic testing services.
- Profit Margin of 11.5%, demonstrating the company's ability to generate profit from its revenue.
- Beta of 1.02, indicating the stock's volatility is similar to the overall market.
Competitors & Peers
Strengths
- Proprietary PathFinderTG platform.
- Specialized focus on pancreatic and thyroid cancer diagnostics.
- Established relationships with key physicians and hospitals.
- Strong gross margin of 64.6%.
Weaknesses
- Small market capitalization of $0.01B.
- Limited geographic reach (primarily United States).
- Dependence on reimbursement policies for revenue.
- Competition from larger diagnostic companies.
Catalysts
- Ongoing: Expansion of PancraGEN testing services for pancreatic cancer risk assessment.
- Ongoing: Increased adoption of ThyGeNEXT oncogenic mutation panel for thyroid nodules.
- Upcoming: Potential partnerships with hospitals and clinics to integrate diagnostic tests into clinical workflows.
- Upcoming: Development of new diagnostic assays for other types of cancer leveraging the PathFinderTG platform.
- Ongoing: Geographic expansion into international markets to tap into growing demand for molecular diagnostic tests.
Risks
- Potential: Changes in reimbursement policies impacting revenue from diagnostic testing services.
- Ongoing: Competition from established diagnostic companies with greater resources and market share.
- Potential: Technological advancements rendering existing tests obsolete.
- Ongoing: Regulatory challenges and compliance requirements in the healthcare industry.
- Potential: Limited financial disclosure and liquidity due to trading on the OTC Other market.
Growth Opportunities
- Expansion of PancraGEN Testing: Interpace Biosciences can expand the market penetration of its PancraGEN test for pancreatic cyst and pancreaticobiliary lesion risk assessment. The market for pancreatic cancer diagnostics is projected to grow as early detection improves patient outcomes. By increasing awareness and adoption of PancraGEN among gastroenterologists and oncologists, Interpace can drive revenue growth. Timeline: Ongoing.
- Increased Adoption of ThyGeNEXT: The ThyGeNEXT oncogenic mutation panel for thyroid nodules represents a significant growth opportunity. As guidelines for thyroid nodule management evolve, molecular testing is becoming increasingly important. Interpace can focus on educating endocrinologists and surgeons about the benefits of ThyGeNEXT in improving diagnostic accuracy and reducing unnecessary surgeries. Timeline: Ongoing.
- Strategic Partnerships with Hospitals and Clinics: Forming strategic partnerships with hospitals and clinics can provide Interpace with a steady stream of patient samples and enhance its market reach. By integrating its diagnostic tests into clinical workflows, Interpace can streamline the testing process and improve turnaround times. These partnerships can also facilitate the collection of valuable clinical data for research and development purposes. Timeline: Ongoing.
- Development of New Diagnostic Assays: Interpace can leverage its PathFinderTG platform to develop new diagnostic assays for other types of cancer. By expanding its test menu, Interpace can address a broader range of clinical needs and diversify its revenue streams. Focus areas could include liquid biopsies for early cancer detection and companion diagnostics for targeted therapies. Timeline: 2027-2028.
- Geographic Expansion: While currently focused on the United States, Interpace Biosciences can explore opportunities to expand its geographic reach into international markets. The demand for molecular diagnostic tests is growing globally, particularly in countries with advanced healthcare systems. By partnering with distributors and establishing local laboratories, Interpace can tap into new markets and accelerate its growth. Timeline: 2028-2030.
Opportunities
- Expansion of PancraGEN and ThyGeNEXT testing services.
- Development of new diagnostic assays for other types of cancer.
- Strategic partnerships with hospitals and clinics.
- Geographic expansion into international markets.
Threats
- Changes in reimbursement policies.
- Competition from established diagnostic companies.
- Technological advancements rendering existing tests obsolete.
- Regulatory challenges and compliance requirements.
Competitive Advantages
- Proprietary PathFinderTG platform enables the development of novel diagnostic assays.
- Established relationships with physicians and hospitals in the United States.
- Strong focus on pancreatic and thyroid cancer diagnostics.
- Expertise in molecular diagnostics and bioinformatics.
About IDXG
Interpace Biosciences, Inc., founded in 1986 and headquartered in Parsippany, New Jersey, provides molecular diagnostic tests, bioinformatics, and pathology services focused on evaluating cancer risk. Originally incorporated as Interpace Diagnostics Group, Inc., the company rebranded in November 2019 to Interpace Biosciences, Inc., reflecting its enhanced focus on innovative bioscience solutions. Interpace's core offerings include PancraGEN, a genomic test designed for pancreatic cysts and pancreaticobiliary solid lesions, aiding physicians in assessing the risk of pancreaticobiliary cancers. This test utilizes the company's proprietary PathFinderTG platform. PanDNA, a molecular-only version of PancraGEN, offers a snapshot of key diagnostic factors. ThyGeNEXT is another key product, an oncogenic mutation panel used to identify malignant thyroid nodules. Additionally, ThyraMIR assesses thyroid nodules for malignancy risk using a microRNA gene-expression assay. RespriDx is a genomic test that helps physicians differentiate metastatic or recurrent lung cancer. Interpace also provides pharmacogenomics testing, genotyping, biorepository, and customized services to pharmaceutical and biotech companies, serving physicians, hospitals, and clinics across the United States.
What They Do
- Provides molecular diagnostic tests for evaluating cancer risk.
- Offers PancraGEN for pancreatic cyst and pancreaticobiliary lesion genomic testing.
- Provides PanDNA, a molecular-only version of PancraGEN.
- Offers ThyGeNEXT, an oncogenic mutation panel for thyroid nodules.
- Provides ThyraMIR for assessing thyroid nodules for malignancy risk.
- Offers RespriDx, a genomic test for differentiating metastatic or recurrent lung cancer.
- Provides pharmacogenomics testing and genotyping services.
- Offers biorepository and customized services to pharmaceutical and biotech industries.
Business Model
- Directly sells molecular diagnostic tests to physicians, hospitals, and clinics.
- Generates revenue through test reimbursement from insurance companies and government payers.
- Offers customized services to pharmaceutical and biotech companies on a contract basis.
- Leverages its PathFinderTG platform to develop and commercialize new diagnostic assays.
Industry Context
Interpace Biosciences, Inc. operates in the rapidly evolving medical diagnostics and research industry. The market is driven by increasing demand for personalized medicine and early cancer detection. Competitive landscape includes companies offering similar molecular diagnostic tests, such as AVCRF, CPIVF, ICBU, LIFD, and RMSL. The industry is characterized by continuous innovation and regulatory scrutiny. Interpace's focus on pancreatic and thyroid cancer diagnostics positions it within a niche market with specific clinical needs.
Key Customers
- Physicians specializing in gastroenterology, oncology, and endocrinology.
- Hospitals and clinics offering diagnostic testing services.
- Pharmaceutical and biotech companies requiring pharmacogenomics and genotyping services.
- Patients seeking early cancer detection and personalized treatment options.
Financials
Chart & Info
Interpace Biosciences, Inc. (IDXG) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Nov 26, 2019
-
Stocks That Hit 52-Week Lows On Monday
· Nov 25, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IDXG.
Price Targets
Wall Street price target analysis for IDXG.
MoonshotScore
What does this score mean?
The MoonshotScore rates IDXG's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Thomas W. Burnell
CEO
Thomas W. Burnell serves as the CEO of Interpace Biosciences, Inc. His background includes extensive experience in the healthcare and diagnostics industries. Prior to joining Interpace, Burnell held leadership positions at various healthcare companies, focusing on strategic planning, business development, and commercial operations. He has a proven track record of driving growth and innovation in the diagnostics sector. His expertise includes molecular diagnostics, personalized medicine, and healthcare reimbursement.
Track Record: Under Thomas W. Burnell's leadership, Interpace Biosciences, Inc. has focused on expanding its molecular diagnostic testing services, particularly in the areas of pancreatic and thyroid cancer. He has overseen the development and commercialization of new diagnostic assays and has worked to strengthen the company's relationships with key physicians and hospitals. His strategic decisions have aimed to improve the company's financial performance and market position.
IDXG OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Interpace Biosciences, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater risks. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, which can result in less transparency and investor protection.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower trading volume and liquidity can lead to price volatility.
- OTC Other companies may be subject to less regulatory oversight.
- Potential for delisting or trading suspensions.
- Higher risk of fraud or manipulation compared to exchange-listed stocks.
- Verify the company's financial statements and SEC filings (if available).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's OTC Markets profile for any disclosures or warnings.
- Check for any legal or regulatory issues involving the company.
- Monitor trading volume and price activity for unusual patterns.
- Consult with a financial advisor before investing.
- Established business operations with a history dating back to 1986.
- Focus on molecular diagnostics and cancer risk assessment.
- Proprietary PathFinderTG platform and diagnostic assays.
- Relationships with physicians, hospitals, and pharmaceutical companies.
- CEO with experience in the healthcare and diagnostics industries.
Common Questions About IDXG
What does Interpace Biosciences, Inc. do?
Interpace Biosciences, Inc. is a molecular diagnostics company that provides tests and services for assessing cancer risk. They offer a range of diagnostic solutions, including PancraGEN for pancreatic cysts, ThyGeNEXT for thyroid nodules, and RespriDx for lung cancer. Their business model revolves around selling these tests to physicians, hospitals, and clinics, and generating revenue through insurance reimbursement and direct sales. The company leverages its proprietary PathFinderTG platform to develop and commercialize new diagnostic assays, positioning itself as a key player in the personalized medicine space.
What do analysts say about IDXG stock?
As of March 17, 2026, a comprehensive analyst consensus for IDXG is not readily available due to its OTC listing and smaller market capitalization. However, key valuation metrics such as the P/E ratio of 1.56 and gross margin of 64.6% suggest potential value. Growth considerations include the company's ability to expand its test menu, secure favorable reimbursement policies, and penetrate new markets. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.
What are the main risks for IDXG?
The main risks for Interpace Biosciences, Inc. include changes in reimbursement policies, competition from larger diagnostic companies, technological advancements rendering existing tests obsolete, and regulatory challenges in the healthcare industry. As an OTC-listed company, IDXG also faces risks related to limited financial disclosure, lower trading volume, and potential price volatility. Investors should carefully assess these risks before investing in IDXG.
What are the key factors to evaluate for IDXG?
Interpace Biosciences, Inc. (IDXG) currently holds an AI score of 51/100, indicating moderate score. Key strength: Proprietary PathFinderTG platform.. Primary risk to monitor: Potential: Changes in reimbursement policies impacting revenue from diagnostic testing services.. This is not financial advice.
How frequently does IDXG data refresh on this page?
IDXG prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IDXG's recent stock price performance?
Recent price movement in Interpace Biosciences, Inc. (IDXG) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary PathFinderTG platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider IDXG overvalued or undervalued right now?
Determining whether Interpace Biosciences, Inc. (IDXG) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying IDXG?
Before investing in Interpace Biosciences, Inc. (IDXG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC market data may be less reliable than exchange-listed data.
- Analyst coverage may be limited due to the company's size and OTC listing.